213 related articles for article (PubMed ID: 29348196)
1. Placental Findings and Effect of Prophylactic Hydrocortisone in Extremely Preterm Infants.
Héneau A; Guimiot F; Mohamed D; Rideau Batista Novais A; Alberti C; Baud O;
Pediatrics; 2018 Feb; 141(2):. PubMed ID: 29348196
[TBL] [Abstract][Full Text] [Related]
2. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
Baud O; Maury L; Lebail F; Ramful D; El Moussawi F; Nicaise C; Zupan-Simunek V; Coursol A; Beuchée A; Bolot P; Andrini P; Mohamed D; Alberti C;
Lancet; 2016 Apr; 387(10030):1827-36. PubMed ID: 26916176
[TBL] [Abstract][Full Text] [Related]
3. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial.
Onland W; Cools F; Kroon A; Rademaker K; Merkus MP; Dijk PH; van Straaten HL; Te Pas AB; Mohns T; Bruneel E; van Heijst AF; Kramer BW; Debeer A; Zonnenberg I; Marechal Y; Blom H; Plaskie K; Offringa M; van Kaam AH;
JAMA; 2019 Jan; 321(4):354-363. PubMed ID: 30694322
[TBL] [Abstract][Full Text] [Related]
4. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age.
Baud O; Trousson C; Biran V; Leroy E; Mohamed D; Alberti C;
JAMA; 2017 Apr; 317(13):1329-1337. PubMed ID: 28384828
[TBL] [Abstract][Full Text] [Related]
5. Association between Baseline Cortisol Serum Concentrations and the Effect of Prophylactic Hydrocortisone in Extremely Preterm Infants.
Renolleau C; Toumazi A; Bourmaud A; Benoist JF; Chevenne D; Mohamed D; Alberti C; Biran V; Baud O;
J Pediatr; 2021 Jul; 234():65-70.e3. PubMed ID: 33359303
[TBL] [Abstract][Full Text] [Related]
6. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.
Watterberg KL; Walsh MC; Li L; Chawla S; D'Angio CT; Goldberg RN; Hintz SR; Laughon MM; Yoder BA; Kennedy KA; McDavid GE; Backstrom-Lacy C; Das A; Crawford MM; Keszler M; Sokol GM; Poindexter BB; Ambalavanan N; Hibbs AM; Truog WE; Schmidt B; Wyckoff MH; Khan AM; Garg M; Chess PR; Reynolds AM; Moallem M; Bell EF; Meyer LR; Patel RM; Van Meurs KP; Cotten CM; McGowan EC; Hines AC; Merhar S; Peralta-Carcelen M; Wilson-Costello DE; Kilbride HW; DeMauro SB; Heyne RJ; Mosquera RA; Natarajan G; Purdy IB; Lowe JR; Maitre NL; Harmon HM; Hogden LA; Adams-Chapman I; Winter S; Malcolm WF; Higgins RD;
N Engl J Med; 2022 Mar; 386(12):1121-1131. PubMed ID: 35320643
[TBL] [Abstract][Full Text] [Related]
7. Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants.
Gudmundsdottir A; Johansson S; Håkansson S; Norman M; Källen K; Bonamy AK
Neonatology; 2015; 107(2):87-92. PubMed ID: 25412681
[TBL] [Abstract][Full Text] [Related]
8. Relationship between placental autophagy and inflammasome activities with morbidity of extremely preterm infants.
Deliloğlu B; Tüzün F; Aysal A; Duman N; Özkan H; Özer E
Turk J Pediatr; 2022; 64(6):1001-1012. PubMed ID: 36583882
[TBL] [Abstract][Full Text] [Related]
9. Bronchopulmonary dysplasia-associated pulmonary hypertension: clues from placental pathology.
Kunjunju AM; Gopagondanahalli KR; Chan Y; Sehgal A
J Perinatol; 2017 Dec; 37(12):1310-1314. PubMed ID: 28880261
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic hydrocortisone in extremely preterm infants and brain MRI abnormality.
Alison M; Tilea B; Toumazi A; Biran V; Mohamed D; Alberti C; Bourmaud A; Baud O;
Arch Dis Child Fetal Neonatal Ed; 2020 Sep; 105(5):520-525. PubMed ID: 31980445
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis.
Morris IP; Goel N; Chakraborty M
Eur J Pediatr; 2019 Aug; 178(8):1171-1184. PubMed ID: 31144162
[TBL] [Abstract][Full Text] [Related]
12. Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia.
Bassler D; Plavka R; Shinwell ES; Hallman M; Jarreau PH; Carnielli V; Van den Anker JN; Meisner C; Engel C; Schwab M; Halliday HL; Poets CF;
N Engl J Med; 2015 Oct; 373(16):1497-506. PubMed ID: 26465983
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic postnatal corticosteroids: Early hydrocortisone.
Baud O; Watterberg KL
Semin Fetal Neonatal Med; 2019 Jun; 24(3):202-206. PubMed ID: 31043325
[TBL] [Abstract][Full Text] [Related]
14. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan.
Onland W; Merkus MP; Nuytemans DH; Jansen-van der Weide MC; Holman R; van Kaam AH;
Trials; 2018 Mar; 19(1):178. PubMed ID: 29523175
[TBL] [Abstract][Full Text] [Related]
15. Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants.
Jensen EA; Dysart KC; Gantz MG; Carper B; Higgins RD; Keszler M; Laughon MM; Poindexter BB; Stoll BJ; Walsh MC; Schmidt B;
J Pediatr; 2017 Jul; 186():34-40.e2. PubMed ID: 28258737
[TBL] [Abstract][Full Text] [Related]
16. The beneficial effect of prophylactic hydrocortisone treatment in extremely preterm infants improves upon adjustment of the baseline characteristics.
Baud O; Lehert P;
Pediatr Res; 2024 Jan; 95(1):251-256. PubMed ID: 37653218
[TBL] [Abstract][Full Text] [Related]
17. Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth.
Baud O; Trousson C; Biran V; Leroy E; Mohamed D; Alberti C;
Arch Dis Child Fetal Neonatal Ed; 2019 Jan; 104(1):F30-F35. PubMed ID: 29321180
[TBL] [Abstract][Full Text] [Related]
18. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.
Onland W; Offringa M; Cools F; De Jaegere AP; Rademaker K; Blom H; Cavatorta E; Debeer A; Dijk PH; van Heijst AF; Kramer BW; Kroon AA; Mohns T; van Straaten HL; te Pas AB; Theyskens C; van Weissenbruch MM; van Kaam AH
BMC Pediatr; 2011 Nov; 11():102. PubMed ID: 22070744
[TBL] [Abstract][Full Text] [Related]
19. Hydrocortisone use in ventilated extremely preterm infants decreased bronchopulmonary dysplasia with no effects on neurodevelopment after two years.
Renault A; Patkaï J; Dassieu G; El Ayoubi M; Canouï-Poitrine F; Durrmeyer X
Acta Paediatr; 2016 Sep; 105(9):1047-55. PubMed ID: 27239054
[TBL] [Abstract][Full Text] [Related]
20. Neurocognitive outcomes at age 5 years after prophylactic hydrocortisone in infants born extremely preterm.
Trousson C; Toumazi A; Bourmaud A; Biran V; Baud O
Dev Med Child Neurol; 2023 Jul; 65(7):926-932. PubMed ID: 36417367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
